3 patients had PR, 8 had SD, CBR of 31.4%. Median duration of clinical benefit was 6.8 mo.Anti-tumor immunity activated in post-treatment biopsies as seen with methylomic & transcriptomic analyses.PBMCs showed higher frequency of naive &/or central memory CD4+ T cells and classical monocytes in patients with a durable CBR. This evidence concerns the gene CD4 and neoplasm.